We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+6.31%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$852M
AUM Growth
+$151M
Cap. Flow
+$154M
Cap. Flow %
18.03%
Top 10 Hldgs %
46.73%
Holding
164
New
33
Increased
26
Reduced
31
Closed
28

Top Buys

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$28.9M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$14.6M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$9.62M
4
FOLD
Amicus Therapeutics
FOLD
+$9.34M
5
PRTA icon
Prothena Corp
PRTA
+$7.38M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$18.6M
2
BIIB icon
Biogen
BIIB
+$9.88M
3
ITRN icon
Ituran Location and Control
ITRN
+$8.27M
4
ORBK
Orbotech Ltd
ORBK
+$6.41M
5
ZGNX
Zogenix, Inc.
ZGNX
+$5.08M

Sector Composition

Rank Sector Weight
1 Healthcare 58.93%
2 Technology 3.62%
3 Communication Services 2.25%
4 Financials 1.01%
5 Consumer Discretionary 0.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ORLY icon
76
O'Reilly Automotive
ORLY
$72.9B
$2.8M 0.33%
174,750
+149,250
+585% +$2.22M
EXPE icon
77
Expedia Group
EXPE
$35.4B
$2.75M 0.32%
+22,950
New +$2.98M
CRBP icon
78
Corbus Pharmaceuticals
CRBP
$166M
$2.66M 0.31%
+12,500
New +$2.68M
PHXM
79
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$2.64M 0.31%
+12,000
New +$2.83M
MGNX icon
80
MacroGenics
MGNX
$235M
$2.63M 0.31%
138,700
-70,000
-34% -$1.31M
CASC
81
DELISTED
Cascadian Therapeutics, Inc.
CASC
$2.52M 0.3%
681,210
– –
SMMT icon
82
Summit Therapeutics
SMMT
$10.4B
$2.35M 0.28%
212,018
– –
PANW icon
83
Palo Alto Networks
PANW
$270B
$2.33M 0.27%
96,330
-28,500
-23% -$693K
CRVS icon
84
Corvus Pharmaceuticals
CRVS
$1.12B
$2.29M 0.27%
221,430
– –
ARDX icon
85
Ardelyx
ARDX
$1.22B
$2.28M 0.27%
345,000
– –
CPRX
86
DELISTED
Catalyst Pharmaceutical
CPRX
$2.25M 0.26%
+576,825
New +$1.91M
TEVA icon
87
Teva Pharmaceuticals
TEVA
$40.8B
$2.25M 0.26%
118,750
-281,250
-70% -$4.23M
RNAC icon
88
Cartesian Therapeutics
RNAC
$229M
$2.24M 0.26%
7,618
– –
CTIC
89
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$2.23M 0.26%
833,633
– –
CBAY
90
DELISTED
Cymabay Therapeutics
CBAY
$2.21M 0.26%
+240,000
New +$2.05M
ORBK
91
DELISTED
Orbotech Ltd
ORBK
$2.19M 0.26%
43,488
-131,755
-75% -$6.41M
SNDX icon
92
Syndax Pharmaceuticals
SNDX
$1.69B
$2.18M 0.26%
248,472
– –
GLMD icon
93
Galmed Pharmaceuticals
GLMD
$5.13M
$2.16M 0.25%
+1,323
New +$1.95M
VTRS icon
94
CALL
Viatris
VTRS
$20.4B
$2.12M 0.25%
50,000
-100,000
-67% -$3.82M
AAP icon
95
CALL
Advance Auto Parts
AAP
$3.35B
$2.09M 0.25%
21,000
– –
SRRA
96
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$2.05M 0.24%
+13,750
New +$1.32M
CMCSA icon
97
Comcast
CMCSA
$85B
$1.88M 0.22%
46,905
-19,455
-29% -$731K
KALA icon
98
KALA BIO
KALA
$14.1M
$1.85M 0.22%
+40
New +$1.87M
OVID icon
99
Ovid Therapeutics
OVID
$414M
$1.78M 0.21%
180,674
-125,000
-41% -$1.15M
MA icon
100
Mastercard
MA
$502B
$1.74M 0.2%
11,525
– –
2 3
4
5 6

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q4 2017 Portfolio in Review

As of Q4 2017, Sphera Funds Management held 164 positions worth $852M, up 22% from $701M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Sphera Funds Management deployed $154M of net new capital in Q4 2017, opening 33 new positions and adding to 26 existing holdings. Its largest new stake was Viatris: 756,449 shares worth $32M.

By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 63% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Biogen, an estimated $9.88M trimmed.

  • Sphera Funds Management's largest Q4 2017 buy was Viatris: 756,449 shares worth $32M.
  • Sphera Funds Management added most to Vertex Pharmaceuticals in Q4 2017, an estimated $9.62M increase.
  • Sphera Funds Management's biggest Q4 2017 reduction was Biogen, cutting an estimated $9.88M.
  • Sphera Funds Management fully exited Gilead Sciences in Q4 2017, selling an estimated $18.6M.
  • Sphera Funds Management's ten largest holdings make up 47% of its $852M portfolio in Q4 2017.
  • Sphera Funds Management opened 33 new positions and closed 28 in Q4 2017.
  • Sphera Funds Management's portfolio value rose 22% quarter-over-quarter to $852M.

Based on Sphera Funds Management's 13F filing for Q4 2017, filed 12 Feb 2018.